Boehringer Ingelheim says its investigational kidney drug apecotrep reduced proteinuria by 40% compared with placebo in a Phase 2 clinical trial involving patients with primary focal segmental glomerulosclerosis.
Faced with a legal deadline for a response, FDA denies without comment on the specifics a law firm’s petition seeking restrictions on approval of generic Ozempic.
Boehringer Ingelheim says its investigational kidney drug apecotrep reduced proteinuria by 40% compared with placebo in a Phase 2 clinical trial involving patients with primary focal segmental glomerulosclerosis.
Faced with a legal deadline for a response, FDA denies without comment on the specifics a law firm’s petition seeking restrictions on approval of generic Ozempic.
FDA warns Malaysia’s Fulijaya Manufacturing about CGMP violations in its production of finished drugs.
A Friends of Cancer Research white paper explores the emerging role of AI-enabled tumor assessment tools and the framework needed to use them in validating trial endpoints.
